Wuxi Biologics (Cayman) (1FW2) AI Stock Analysis

Wuxi Biologics (Cayman)

(Frankfurt:1FW2)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Integrated biologics CDMO platformThe integrated service offering supports customers across multiple stages of biologics development, allowing Wuxi Biologics to participate beyond a single project milestone. This breadth can deepen customer relationships, create repeat opportunities as molecules advance, and support durable demand for outsourced development and manufacturing.

Negative Factors

Recent revenue growth slowdownThe sharp deceleration in reported revenue growth indicates that the company is not currently expanding at the pace suggested by its longer-term history. If this slower trajectory persists, it could limit operating leverage, reduce the pace of earnings growth, and make future performance more dependent on project progression and utilization.

Wuxi Biologics (Cayman) (1FW2) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 23.40B
Dividend Yield: ―
Average Volume (3M): 1,405
Price to Earnings (P/E): 31.1
Beta (1Y): 1.16
Revenue Growth: 13.33%
EPS Growth: 13.46%
Country: Germany
Employees: 14,705
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Wuxi Biologics (Cayman) Business Overview & Revenue Model

Company Description

Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturin...

Wuxi Biologics (Cayman) Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:1FW2 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:1873	73Outperform	HKD 2.60B	12.89	4.45%	―	7.38%	7.90%
HK:1548	71Outperform	HKD 79.58B	-14.95	-16.23%	―	53.48%	-120.02%
HK:2315	69Neutral	HKD 17.02B	38.16	15.94%	―	48.04%	166.72%
HK:1521	63Neutral	HKD 3.04B	36.53	3.02%	―	10.32%	178.23%
HK:3759	53Neutral	HKD 80.45B	41.79	10.93%	0.85%	24.21%	19.72%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:1FW2 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:1FW2	Wuxi Biologics (Cayman)	5.13	1.21	30.73%
HK:1548	Genscript Biotech Corporation	35.02	17.98	105.52%
HK:3759	Pharmaron Beijing Co., Ltd. Class H	26.98	1.65	6.50%
HK:1521	Frontage Holdings Corp.	1.49	0.32	27.35%
HK:1873	Viva Biotech Holdings	1.25	-1.14	-47.70%
HK:2315	Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H	38.30	9.06	30.98%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Wuxi Biologics (Cayman) AI Stock Analysis